HR and breast carcinoma: Furthermore, less than 50% of patients with HR+, HER2− advanced breast cancer are prescribed CDK4/6 inhibitors as first‐line treatment [51, 52, 53, 54] despite approvals in the first‐line setting, illustrating the continued relevance of the SANDPIPER population to a real‐world setting.